Dr. McKay on Unmet Needs for RCC

Rana R. McKay, MD
Published: Thursday, Feb 22, 2018



Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses unmet needs for patients with renal cell carcinoma (RCC).

McKay says that one of the biggest unmet needs is the management of patients with nonclear cell RCC. This population is comprised of a heterogeneous group of patients with multiple histologies, and is historically excluded from clinical trials. Targeting this rare patient population to improve outcomes is going to be an important step forward, says McKay. There are several trials that are investigating various combinations of immunotherapy, but more work is needed to help improve the management of patients with nonclear cell RCC.

Additionally, due to the unmet need of patients with bone metastases, there is a trial investigating a VEGF inhibitor and radium-223 (Xofigo) in patients with RCC and bone metastases. Data from a phase I pilot study of the combination of radium-223 with a VEGF-targeted therapy were recently released.
 
SELECTED
LANGUAGE


Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses unmet needs for patients with renal cell carcinoma (RCC).

McKay says that one of the biggest unmet needs is the management of patients with nonclear cell RCC. This population is comprised of a heterogeneous group of patients with multiple histologies, and is historically excluded from clinical trials. Targeting this rare patient population to improve outcomes is going to be an important step forward, says McKay. There are several trials that are investigating various combinations of immunotherapy, but more work is needed to help improve the management of patients with nonclear cell RCC.

Additionally, due to the unmet need of patients with bone metastases, there is a trial investigating a VEGF inhibitor and radium-223 (Xofigo) in patients with RCC and bone metastases. Data from a phase I pilot study of the combination of radium-223 with a VEGF-targeted therapy were recently released.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x